About NBP

Founded: 2014
Employees: 30
CEO: Srishti Gupta
WebsiteView website: novabridge.com

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Recent NBP News & Updates

Announcement • Jun 29

Novabridge Biosciences Announces Appointment of Srishti Gupta as Member of the Board of Directors, Effective July 1, 2026

NovaBridge Biosciences announced the appointment of Srishti Gupta, MD MPP as a member of the Company's Board of Directors, effective July 1, 2026. Dr. Srishti Gupta is a physician-executive with more than two decades of leadership experience across biopharmaceuticals, global health, and strategy. Most recently, she served as Chief Executive Officer of Idorsia Ltd. Appointed to lead the company after four years on its board of directors, she executed a full operational and financial turnaround. Earlier in her career, Dr. Gupta spent 18 years at McKinsey & Company, where she led the firm’s Global Health Practice for more than a decade and built large-scale public-private partnerships across the United States, Europe, and emerging markets. She advised life sciences companies and governments on strategy, growth, market access, and organizational transformation, and served on the faculty of the MIT Sloan School of Management. Dr. Gupta serves as a member of the board of Santhera Pharmaceuticals. She has previously served on the boards of directors of Invivyd Inc., where she chaired the Compensation Committee, and Idorsia Ltd., where she chaired the Nominations Governance and Compensation Committee. She also serves as a member of the board of directors of Partners In Health and a Board Trustee of the International Vaccine Institute. Dr. Gupta holds a Doctor of Medicine from Harvard Medical School; a Master of Public Policy in international development from Harvard Kennedy School; a Master of Philosophy in Natural Sciences from the University of Cambridge; and a Master of Arts in Molecular and Cellular Biology and a Bachelor of Arts in Biological Sciences, both from Harvard University.

Recent updates

No updates

NovaBridge Biosciences Stock Price

NBP Share Price Performance

NBP Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

NovaBridge Biosciences Key Details

About NBP

Recent NBP News & Updates

NovaBridge Biosciences, Annual General Meeting, Sep 08, 2026

NovaBridge: Rebranded, Repackaged, But Far From De-Risked

Novabridge Biosciences Announces Appointment of Srishti Gupta as Member of the Board of Directors, Effective July 1, 2026

Recent updates

NovaBridge Biosciences Competitors

Immix Biopharma

REGENXBIO

Altimmune

ARS Pharmaceuticals